Photo of Kevin Elias,  MD

Kevin Elias, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-8840


kelias@bwh.harvard.edu

Kevin Elias, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Director, Gynecologic Oncology Laboratory, Division of Gynecologic Oncology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My laboratory focuses on the prevention, diagnosis, and treatment of women with gynecologic cancers. Our group includes a mixture of gynecologic oncology fellows, post-doctoral PhDs, technicians, and support staff. The thrust of our work is devoted to the early diagnosis of ovarian cancer, novel treatment approaches based on polymer chemistry, and in vivo models of gynecologic malignancies, including choriocarcinoma and ovarian cancer.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Braga A, Lopes R, Campos V, Freitas F, Maestá I, Sun SY, Pedrotti LG, Bessel M, de Sousa CB, Leal E, Yela D, Uberti E, Madi JM, Viggiano M, Junior JA, Filho JR, Elias KM, Horowitz NS, Berkowitz RS. The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women. Gynecol Oncol 2023; 176:130-138. PubMed
  • Sasamoto N, Elias KM. Early Detection of Ovarian Cancer. Cold Spring Harb Perspect Med 2023. PubMed
  • Gerton TJ, Green A, Campisi M, Chen M, Gjeci I, Mahadevan N, Lee CAA, Mishra R, Vo HV, Haratani K, Li ZH, Hasselblatt KT, Testino B, Connor T, Lian CG, Elias KM, Lizotte P, Ivanova EV, Barbie DA, Dinulescu DM. Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells. Cancers (Basel) 2023. PubMed
  • Elias KM, Ng NW, Dam KU, Milne A, Disler ER, Gockley A, Holub N, Seshan ML, Church GM, Ginsburg ES, Anchan RM. Fertility restoration in mice with chemotherapy induced ovarian failure using differentiated iPSCs. EBioMedicine 2023; 94:104715. PubMed
  • Silva VARD, Maestá I, Costa RAA, Campos AÁ, Braga A, Horowitz N, Elias KM, Berkowitz R. Geographical Health District and Distance Traveled Influence on Clinical Status at Admission of Patients with Gestational Trophoblastic Disease. Rev Bras Ginecol Obstet 2023; 45:e384-e392. PubMed
  • Elias K, Smyczynska U, Stawiski K, Nowicka Z, Webber J, Kaplan J, Landen C, Lubinski J, Mukhopadhyay A, Chakraborty D, Connolly DC, Symecko H, Domchek SM, Garber JE, Konstantinopoulos P, Fendler W, Chowdhury D. Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles. Nat Commun 2023; 14:3350. PubMed
  • Greytak SR, Engel KB, Hoon DSB, Elias KM, Lockwood CM, Guan P, Moore HM. Evidence-based procedures to improve the reliability of circulating miRNA biomarker assays. Clin. Chem. Lab. Med. 2023. PubMed
  • Alimena S, Fallah P, Stephenson B, Feltmate C, Feldman S, Elias KM. Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes. Gynecol Oncol 2023; 171:31-38. PubMed
  • Braga A, Andrade T, do Carmo Borges de Souza M, Campos V, Freitas F, Maestá I, Sun SY, Pedrotti LG, Bessel M, Junior JA, Filho JR, Elias KM, Horowitz NS, Berkowitz RS. Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and literat Gynecol Oncol 2023; 170:179-185. PubMed
  • Jareemit N, Therasakvichya S, Freitas F, Paiva G, Ramírez LAC, Berkowitz RS, Horowitz NS, Maestá I, Fülöp V, Braga A, Elias KM. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study. Gynecol Oncol 2023; 170:114-122. PubMed
  • Braga A, Balthar E, Souza LCS, Samora M, Rech M, Madi JM, Junior JA, Filho JR, Elias KM, Horowitz NS, Sun SY, Berkowitz RS. Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases. Clinics 2023; 78:100260. PubMed
  • Abbas-Aghababazadeh F, Sasamoto N, Townsend MK, Huang T, Terry KL, Vitonis AF, Elias KM, Poole EM, Hecht JL, Tworoger SS, Fridley BL. Predictors of residual disease after debulking surgery in advanced stage ovarian cancer. 2023; 13:1090092. PubMed
  • Braga A, Paiva G, Cattai CJ, Elias KM, Horowitz NS, Berkowitz RS. Current chemotherapeutic options for the treatment of gestational trophoblastic disease. Expert Opin Pharmacother 2022. PubMed
  • Campos V, Paiva G, Padron L, Freitas F, Pedrotti LG, Sun SY, Viggiano M, Oliveira L, Rohr L, Madi JM, Arrym TP, Oliveira P, Dos Santos Esteves APV, Junior JA, Filho JR, Elias KM, Horowitz NS, Braga A, Berkowitz RS. Influence of COVID-19 pandemic on molar pregnancy and postmolar gestational trophoblastic neoplasia: An observational study. BJOG 2022. PubMed
  • Bolton KL, Chen D, Corona de la Fuente RI, Fu Z, Murali R, K Bel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ, Moukarzel LA, Winham SJ, Armasu SM, Lester J, Elishaev E, Laslavic A, Kennedy CJ, Piskorz A, Sekowska M, Brand AH, Chiew YE, Pharoah P, Elias KM, Drapkin R, Churchman M, Gourley C, DeFazio A, Karlan B, Brenton JD, Weigelt B, Anglesio MS, Huntsman D, Gayther SA, Konner J, Modugno F, Lawrenson K, Goode EL, Papaemmanuil E. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res 2022. PubMed
  • Ramírez LAC, Maestá I, Bianconi MI, Jankilevich G, Otero S, Mejía CRV, Cortés-Charry R, Elias KM, Horowitz NS, Seckl M, Berkowitz RS. Clinical Presentation, Treatment Outcomes, and Resistance-related Factors in South American Women with Low-risk Postmolar Gestational Trophoblastic Neoplasia. Rev Bras Ginecol Obstet 2022. PubMed
  • Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC, Lu KH, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer. Cancers (Basel) 2022. PubMed
  • Fraser CC, Jia B, Hu G, Al Johani LI, Fritz-Klaus R, Ham JD, Fichorova RN, Elias KM, Cramer DW, Patankar MS, Chen J. Ovarian Cancer Ascites Inhibits Transcriptional Activation of NK Cells Partly through CA125. J Immunol 2022; 208:2227-2238. PubMed
  • Webber JW, Elias KM. Fast and robust imputation for miRNA expression data using constrained least squares. BMC Bioinformatics 2022; 23:145. PubMed
  • Georgiou M, Ntavelou P, Stokes W, Roy R, Maher GJ, Stoilova T, Rakhit CP, Martins M, Ajuh P, Horowitz N, Berkowitz RS, Elias K, Seckl MJ, Pardo OE. ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma. Oncogene 2022; 41:2540-2554. PubMed
  • Lakatos K, González G, Hoballah J, Brooker J, Jeong S, Evans C, Krauledat P, Hansen WP, Elias KM, Patankar M, Fülöp V, Konstantinopoulos PA, Cramer DW. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer. 2022; 15:28. PubMed
  • Parrish RH, Findley R, Elias KM, Kramer B, Johnson EG, Gramlich L, Nelson GS. Pharmacotherapeutic prophylaxis and post-operative outcomes within an Enhanced Recovery After Surgery (ERAS®) program: A randomized retrospective cohort study. Ann Med Surg (Lond) 2022; 73:103178. PubMed
  • Gockley A, Pagacz K, Fiascone S, Stawiski K, Holub N, Hasselblatt K, Cramer DW, Fendler W, Chowdhury D, Elias KM. A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers. 2022; 12:786154. PubMed
  • Braga A, Canelas AC, Torres B, Maesta I, Giongo Pedrotti L, Bessel M, Vieira Dos Santos Esteves AP, Amim Junior J, Rezende Filho J, Elias KM, Horowitz NS, Berkowitz RS. Neutrophil/lymphocyte ratio and other blood cell component counts are not associated with the development of postmolar gestational trophoblastic neoplasia. PLoS ONE 2022; 17:e0277892. PubMed
  • Branco-Silva M, Maesta I, Elias K, Berkowitz RS, Abbade JF, Horowitz NS. Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol. BMJ Open 2022; 12:e059484. PubMed
  • Chandrasekaran A, Elias KM. Synthetic Lethality in Ovarian Cancer. Mol Cancer Ther 2021; 20:2117-2128. PubMed
  • Brummelhuis IS, Fiascone SJ, Hasselblatt KT, Frendl G, Elias KM. Voltage-Gated Sodium Channels as Potential Biomarkers and Therapeutic Targets for Epithelial Ovarian Cancer. Cancers (Basel) 2021. PubMed
  • Cunningham JM, Winham SJ, Wang C, Weiglt B, Fu Z, Armasu SM, McCauley BM, Brand AH, Chiew YE, Elishaev E, Gourley C, Kennedy CJ, Laslavic A, Lester J, Piskorz A, Sekowska M, Brenton JD, Churchman M, DeFazio A, Drapkin R, Elias KM, Huntsman DG, Karlan BY, Köbel M, Konner J, Lawrenson K, Papaemmanuil E, Bolton KL, Modugno F, Goode EL. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiol Biomarkers Prev 2021. PubMed
  • Madi JM, Paganella MP, Litvin IE, Viggiano M, Wendland EM, Elias KM, Horowitz NS, Braga A, Berkowitz RS. Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: a systematic review of observational studies and meta-analysis. Am J Obstet Gynecol 2021. PubMed
  • Poli JG, Paiva G, Freitas F, Mora P, Velarde LGC, Junior JA, Filho JR, Elias KM, Horowitz NS, Braga A, Berkowitz RS. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right? Gynecol Oncol 2021. PubMed
  • Braga A, Elias KM, Horowitz NS, Berkowitz RS. Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia. Rev Bras Ginecol Obstet 2021; 43:503-506. PubMed
  • Chung TKH, Doran G, Cheung TH, Yim SF, Yu MY, Worley MJ, Elias KM, Thorner AR, Pedamallu CS, Ojesina AI, Lau KM, Ducar MD, Wong RRY, Wang VW, Nag A, Wollison BM, Dalgarno A, Lee JHS, Yeung SY, Wong L, Horowitz NS, Davis MR, Leung SA, Mu Y, Mok SC, Chan PKS, Lawrence MS, Crum CP, Chiu RWK, Berkowitz RS, Wong YF. Dissection of Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel) 2021. PubMed
  • St Laurent JD, Lin LH, Owen DM, Maestá I, Castaneda A, Hasselblatt KT, Goldstein DP, Horowitz NS, Berkowitz RS, Elias KM. Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia. Reprod Sci 2021. PubMed
  • Li S, Bercow AS, Falzone M, Kalyanaraman R, Worley MJ, Feltmate CM, Pelletier A, Elias KM. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol. Gynecol Oncol 2021. PubMed
  • Tankou JI, Foley O, Falzone M, Kalyanaraman R, Elias KM. Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers. Int J Gynecol Cancer 2021. PubMed
  • Braga A, Elias KM, Horowitz NS, Berkowitz RS. Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. 2021. PubMed
  • Leung SOA, Feldman S, Kalyanaraman R, Shanmugam V, Worley MJ, Berkowitz RS, Horowitz NS, Feltmate CM, Muto MG, Lee LJ, King MT, Einarsson JI, Ajao MO, Elias KM. Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. Am J Reprod Immunol 2021. PubMed
  • Braga A, Paiva G, Ghorani E, Freitas F, Velarde LGC, Kaur B, Unsworth N, Lozano-Kuehne J, Dos Santos Esteves APV, Rezende Filho J, Amim J, Aguiar X, Sarwar N, Elias KM, Horowitz NS, Berkowitz RS, Seckl MJ. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021; 22:1188-1198. PubMed
  • Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res 2021; 81:158-173. PubMed
  • Jareemit N, Horowitz NS, Goldstein DP, Berkowitz RS, Elias KM. Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol 2020; 159:751-757. PubMed
  • Lin LH, Maestá I, St Laurent JD, Hasselblatt KT, Horowitz NS, Goldstein DP, Quade BJ, Sun SY, Braga A, Fisher RA, Berkowitz RS, Elias KM. Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. Am J Obstet Gynecol 2020. PubMed
  • Harvey RA, Elias KM, Lim A, Bercow A, Short D, Horowitz NS, Berkowitz RS, Agarwal R, Seckl MJ. Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study. Curr Probl Cancer 2020. PubMed
  • Jareemit N, Horowitz NS, Goldstein DP, Berkowitz RS, Elias KM. EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. Gynecol Oncol 2020; 158:99-104. PubMed
  • Braga A, Elias KM, Elias KM, Horowitz NS, Berkowitz RS. How to optimize the management of gestational trophoblastic disease during the coronavirus disease era? Am J Obstet Gynecol 2020. PubMed
  • Freitas F, Braga A, Viggiano M, Velarde LGC, Maesta I, Uberti E, Madi JM, Yela D, Fernandes K, Silveira E, Leal E, Sun SY, Dos Santos Esteves APV, Filho JR, Junior JA, Elias KM, Horowitz NS, Berkowitz RS. Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. Gynecol Oncol 2020. PubMed
  • Horowitz NS, Berkowitz RS, Elias KM. Important insights for non-molar choriocarcinoma. BJOG 2020. PubMed
  • Braga A, de Souza Hartung Araújo C, Mora PAR, Paulino E, de Melo AC, Velarde GC, Dos Santos Esteves APV, Junior JA, Filho JR, Elias KM, Horowitz NS, Berkowitz RS. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. Gynecol Oncol 2020; 156:598-605. PubMed
  • Alimena S, Falzone M, Feltmate CM, Prescott K, Contrino Slattery L, Elias K. Perioperative glycemic measures among non-fasting gynecologic oncology patients receiving carbohydrate loading in an enhanced recovery after surgery (ERAS) protocol. Int J Gynecol Cancer 2020. PubMed
  • Maestá I, Nitecki R, Desmarais CCF, Horowitz NS, Goldstein DP, Elias KM, Berkowitz RS. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2020. PubMed
  • Leung SOA, Akinwunmi B, Elias KM, Feldman S. Educating healthcare providers to increase Human Papillomavirus (HPV) vaccination rates: A Qualitative Systematic Review. Vaccine X 2019; 3:100037. PubMed
  • Elias KM, Berkowitz RS, Horowitz NS. State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia. J Natl Compr Canc Netw 2019; 17:1396-1401. PubMed
  • Dejene SB, Ohman AW, Du W, Randhawa D, Bradley A, Yadav N, Elias KM, Dinulescu DM, Setlur SR. Defining fallopian tube-derived miRNA cancer signatures. Cancer Med 2019. PubMed
  • Alimena S, Yang DD, Melamed A, Mahal BA, Worley MJ, Feldman S, Elias KM, Orio PF, Lee LJ, King M. Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecol Oncol 2019; 154:595-601. PubMed
  • Mensah LB, Morton SW, Li J, Xiao H, Quadir MA, Elias KM, Penn E, Richson AK, Ghoroghchian PP, Liu J, Hammond PT. Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer. Bioeng Transl Med 2019; 4:e10131. PubMed
  • Wijk L, Udumyan R, Pache B, Altman AD, Williams LL, Elias KM, McGee J, Wells T, Gramlich L, Holcomb K, Achtari C, Ljungqvist O, Dowdy SC, Nelson G. International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. Am J Obstet Gynecol 2019. PubMed
  • Cheung TH, Yim SF, Yu MY, Worley MJ, Fiascone SJ, Chiu RWK, Lo KWK, Siu NSS, Wong MCS, Yeung ACM, Wong RRY, Chen ZG, Elias KM, Chung TKH, Berkowitz RS, Wong YF, Chan PKS. Liquid biopsy of HPV DNA in cervical cancer. J Clin Virol 2019; 114:32-36. PubMed
  • Mora PAR, Sun SY, Velarde GC, Filho JR, Uberti EH, Dos Santos Esteves APV, Elias KM, Horowitz NS, Braga A, Berkowitz RS. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol 2019. PubMed
  • Elias KM, Berkowitz RS, Horowitz NS. Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough? Gynecol Oncol 2019; 155:1-2. PubMed
  • Elias KM, Guo J, Bast RC. Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am 2018; 32:903-914. PubMed
  • Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, Birrer M, Hirsch MS, Drapkin R, Labidi-Galy SI. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. J Pathol 2018. PubMed
  • Gockley AA, Elias KM. Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. Cancer Treat Rev 2018; 69:66-71. PubMed
  • Cramer DW, Elias KM. Perspectives on Ovarian Cancer From SEER: Today and Tomorrow. Journal of the National Cancer Institute 2018. PubMed
  • Padrón L, Rezende Filho J, Amim Junior J, Sun SY, Charry RC, Maestá I, Elias KM, Horowitz N, Braga A, Berkowitz RS. Manual Compared With Electric Vacuum Aspiration for Treatment of Molar Pregnancy. Obstet Gynecol 2018; 131:652-659. PubMed
  • Braga A, Biscaro A, do Amaral Giordani JM, Viggiano M, Elias KM, Berkowitz RS, Seckl MJ. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? Eur J Obstet Gynecol Reprod Biol 2018; 223:50-55. PubMed
  • Nitecki R, Berkowitz RS, Elias KM, Goldstein DP, Horowitz NS. Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know? Int J Gynecol Cancer 2018. PubMed
  • Dreaden EC, Kong YW, Quadir MA, Correa S, Suárez-López L, Barberio AE, Hwang MK, Shi AC, Oberlton B, Gallagher PN, Shopsowitz KE, Elias KM, Yaffe MB, Hammond PT. RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors. Bioeng Transl Med 2018; 3:26-36. PubMed
  • Maestá I, Nitecki R, Horowitz NS, Goldstein DP, de Freitas Segalla Moreira M, Elias KM, Berkowitz RS. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecol Oncol 2018; 148:161-167. PubMed
  • Worley MJ, Elias KM, Horowitz NS, Quade BJ, Berkowitz RS. Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. Gynecol Oncol 2018; 148:5-11. PubMed
  • Braga A, Campos V, Filho JR, Lin LH, Sun SY, de Souza CB, da Silva RCAF, Leal EAS, Silveira E, Maestá I, Madi JM, Uberti EH, Viggiano M, Elias KM, Horowitz N, Berkowitz RS. Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma? Gynecol Oncol 2017. PubMed
  • Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, Frendl G, Konstantinopoulos P, Crum CP, Kedzierska M, Cramer DW, Chowdhury D. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. Elife 2017. PubMed
  • Dantas PRS, Maestá I, Filho JR, Junior JA, Elias KM, Howoritz N, Braga A, Berkowitz RS. Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? Gynecol Oncol 2017. PubMed
  • Elias KM. Understanding Enhanced Recovery After Surgery Guidelines: An Introductory Approach. 2017; 27:871-875. PubMed
  • Chung TKH, Cheung TH, Yim SF, Yu MY, Chiu RWK, Lo KWK, Lee IPC, Wong RRY, Lau KKM, Wang VW, Worley MJ, Elias KM, Fiascone SJ, Smith DI, Berkowitz RS, Wong YF. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecol Oncol 2017. PubMed
  • Liu CY, Elias KM, Howitt BE, Lee LJ, Feltmate CM. Sentinel lymph node mapping reduces practice pattern variations in surgical staging for endometrial adenocarcinoma: A before and after study. Gynecol Oncol 2017. PubMed
  • Elias KM, Harvey RA, Hasselblatt KT, Seckl MJ, Berkowitz RS. Type I interferons modulate methotrexate resistance in gestational trophoblastic neoplasia. Am J Reprod Immunol 2017. PubMed
  • Elias KM, Emori MM, Westerling T, Long H, Budina-Kolomets A, Li F, MacDuffie E, Davis MR, Holman A, Lawney B, Freedman ML, Quackenbush J, Brown M, Drapkin R. Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight 2016. PubMed
  • Cramer DW, Elias KM. A prognostically relevant miRNA signature for epithelial ovarian cancer. Lancet Oncol. 2016; 17:1032-3. PubMed
  • Braga A, Maestá I, Soares RR, Elias KM, Domingues MA, Barbisan LF, Berkowitz RS. Apoptotic index for prediction of post-molar gestational trophoblastic neoplasia. Am J Obstet Gynecol 2016. PubMed
  • Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep 2016; 14:429-39. PubMed
  • Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecol Oncol 2015; 139:97-103. PubMed
  • Chung TK, Van Hummelen P, Chan PK, Cheung TH, Yim SF, Yu MY, Ducar MD, Thorner AR, MacConaill LE, Doran G, Pedamallu CS, Ojesina AI, Wong RR, Wang VW, Freeman SS, Lau TS, Kwong J, Chan LK, Fromer M, May T, Worley MJ, Esselen KM, Elias KM, Lawrence M, Getz G, Smith DI, Crum CP, Meyerson M, Berkowitz RS, Wong YF. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer 2015. PubMed
  • Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 2014. PubMed
  • Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-6. PubMed
  • Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, O'Shea JJ. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008; 111:1013-20. PubMed
  • Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 2007; 96:1-22. PubMed
Hide